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Abstract
More people are using the cannabis plant as modern basic and clinical science reaffirms and extends
its medicinal uses. Concomitantly, concern and opposition to smoked medicine has occurred, in
part due to the known carcinogenic consequences of smoking tobacco. Are these reactions
justified? While chemically very similar, there are fundamental differences in the pharmacological
properties between cannabis and tobacco smoke. Cannabis smoke contains cannabinoids whereas
tobacco smoke contains nicotine. Available scientific data, that examines the carcinogenic
properties of inhaling smoke and its biological consequences, suggests reasons why tobacco smoke,
but not cannabis smoke, may result in lung cancer.
Tobacco has dramatic negative consequences for those
who smoke it. In addition to its high addiction potential
[1], tobacco is causally associated with over 400,000
deaths yearly in the United States, and has a significant
negative effect on health in general [2]. More specifically,
over 140,000 lung-related deaths in 2001 were attributed
to tobacco smoke [3]. Comparable consequences would
naturally be expected from cannabis smoking since the
burning of plant material in the form of cigarettes gener-
ates a large variety of compounds that possess numerous
biological activities [4].
While cannabis smoke has been implicated in respiratory
dysfunction, including the conversion of respiratory cells
to what appears to be a pre-cancerous state [5], it has not
been causally linked with tobacco related cancers [6] such
as lung, colon or rectal cancers. Recently, Hashibe et al [7]
carried out an epidemiological analysis of marijuana
smoking and cancer. A connection between marijuana
smoking and lung or colorectal cancer was not observed.
These conclusions are reinforced by the recent work of
Tashkin and coworkers [8] who were unable to demon-
strate a cannabis smoke and lung cancer link, despite
clearly demonstrating cannabis smoke-induced cellular
damage.
Furthermore, compounds found in cannabis have been
shown to kill numerous cancer types including: lung can-
cer [9], breast and prostate [10], leukemia and lymphoma
[11], glioma [12], skin cancer [13], and pheochromocy-
toma [14]. The effects of cannabinoids are complex and
sometimes contradicting, often exhibiting biphasic
responses. For example, in contrast to the tumor killing
properties mentioned above, low doses of THC may stim-
ulate the growth of lung cancer cells in vitro [15].
The genotoxic effects of partially oxidized hydrocarbons
created by burning either cannabis or tobacco have been
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widely examined as the likely source of genetic changes
that lead to the carcinogenic state [16]. As a result, the
medical potential of cannabis has been obscured by the
potential negative impact of using a smoked medicine
[17]. Those who deny the validity of "medical marijuana,"
cite that marijuana smoke contains four fold more tars
than does tobacco smoke [18]. Nevertheless, smoking is
often the preferred route of intake by medical cannabis
users because rapid action allows self-titration [19]. Are
the biological consequences of smoking cannabis and
tobacco similar?
Smoke from tobacco and cannabis contains many of the
same carcinogens and tumor promoters [20,21]. How-
ever, cannabis and tobacco have additional pharmacolog-
ical activities, both receptor-dependent and independent,
that result in different biological endpoints. Polycyclic
aromatic hydrocarbons found in smoke are pro-carcino-
gens that are converted to carcinogens by the enzymatic
activity of the cytochrome P4501A1 oxidase protein
(CYP1A1 gene product). Benzo [a] pyrene is converted to
its carcinogenic metabolite diol epoxide, which binds to
specific hyper-mutable nucleotide sequences in the K-ras
oncogene and p53 tumor suppressor [22]. Recent work by
Roth et al. demonstrates that THC treatment of murine
hepatoma cells caused a dose dependent increase in
CYP1A1 gene transcription, while at the same time
directly inhibiting the enzymatic activity of the gene prod-
uct [23]. Thus, despite potentially higher levels of polycy-
clic aromatic hydrocarbons found in cannabis smoke
compared to tobacco smoke (dependent on what part of
the plant is smoked), the THC present in cannabis smoke
should exert a protective effect against pro-carcinogens
that require activation. In contrast, nicotine activates
some CYP1A1 activities, thus potentially increasing the
carcinogenic effects of tobacco smoke [24].
It is worth noting that cytochrome P4501A1 oxidase has
numerous substrates including biologically active lipid
metabolites such as arachidonic acid, and eicosinoids
[25]. These molecules are components of metabolic path-
ways that are interwoven with the synthesis and degrada-
tion of endocannabinoids such as
arachidonylethanolamine (anandamide) [26]. Hence, the
inhibition of cytochrome P4501A1 oxidase by THC is
likely to have multiple biological effects such as possibly
enhancing cannabinoid activities by decreasing their
catabolism.
The need to better understand the biological conse-
quences of tobacco compared to cannabis smoke has been
underscored by recent studies that demonstrate a unique
role for nicotine in the pathogenesis of lung cancer [27].
In order to appreciate potential biological differences
between tobacco and cannabis smoke, the molecular
basis of signal transduction must be considered with
respect to the life and death of cells. Evolution has pro-
vided cells with biochemical feedback loops, checkpoints
that monitor genetic integrity and the overall state of the
cell. Under conditions of sufficient cellular damage, apop-
totic cell death is induced [28]. While a variety of different
biochemical states are consistent with a cell either living
or dying, constant communication between a cell and its
environment is critical for survival of the cell and ulti-
mately the organism.
Cells communicate with each other via specific cell surface
receptors. When bound with their appropriate ligand, the
receptors initiate signaling cascades that alter cellular bio-
chemistry [29]. THC found in cannabis [30] and nicotine
found in tobacco [31] both have specific receptors by
which their corresponding ligands modulate cellular
functions. Interestingly, both cannabinoid [32] and nico-
tine receptors [27] are coupled to the AKT (PKB) signaling
pathway. Activation of either receptor type can induce an
anti-apoptotic state that prevents cell death. However, it is
the context in which the AKT pathway is activated that
determines whether an organism benefits or is harmed by
this anti-apoptotic activity.
Nicotine receptors are widely distributed and are found in
the epithelial cells lining respiratory passages. Cannabi-
noid receptors are also widely distributed, but have not
been reported in respiratory epithelial cells. The differen-
tial expression of receptors may account for the apparent
difference in carcinogenic activity that results from smok-
ing tobacco compared to cannabis. Both types of smoke
contain a complex mixture of compounds, some of which
are carcinogenic. They both contain hot gasses and irritat-
ing particulate matter (tars). However, the anti-apoptotic
response that results from the stimulation of the nicotine
receptors, under mutagenic conditions, creates a worst-
case scenario. The very cells that have accumulated suffi-
cient genetic damage to normally initiate the apoptotic
cascade are prevented from going down this suicidal path
[33] even though it would be best for the organism as a
whole. In contrast, when the AKT pathway is activated in
the brain after head injury [34] or stroke, [35] cannabi-
noids protect against cell death to the organism's benefit.
Likewise, nicotine can also activate the AKT pathway in
the brain in a beneficial manner. For example, activation
of the nicotine receptors, as is also true of cannabinoid
receptors [36], can prevent the brain cell death that results
from exposure to beta amyloid protein [37] as occurs in
Alzheimer's disease.
The impact of receptor and downstream activation is com-
plicated. Both nicotine and cannabinoids have been
shown to effect angiogenesis in a receptor-mediated man-
ner [13]. However, nicotine and tobacco have oppositeHarm Reduction Journal 2005, 2:21 http://www.harmreductionjournal.com/content/2/1/21
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effects on angiogenesis. Nicotine promotes neo-vaculari-
zation along with associated tumor growth, atheroma, up-
regulation of VEGF, and cell migration [38]. In contrast,
cannabinoids promote tumor regression in rodents and
inhibit pro-angiogenic factors [39]. In fact, clinical trials
to treat human glioma with THC have resulted in
decreased levels of VEGF [40].
The signal transduction pathway described above repre-
sents one means by which the carcinogenic affects of
tobacco are amplified in a contrasting manner to what
occurs with cannabis. The immunological effects resulting
from smoking tobacco or cannabis are also distinctive and
result in opposite end-points. Again, the carcinogenic
potential of smoke is increased by tobacco, whereas it is
uniquely reduced by the specific immune regulatory activ-
ity of cannabinoids in cannabis smoke. The introduction
of hot gaseous material containing both carcinogens and
particulate material into the respiratory passages produces
pro-inflammatory immune responses [41]. The inflam-
matory state is a double-edged sword that can serve to
protect or kill an organism. A functional characteristic of
the pro-inflammatory state is the production of free radi-
cals [42]. These reactive chemical species are essential
armaments in the body's defense against various patho-
gens, in particular against intracellular parasites and bac-
teria. Free radicals are thought to be contributing
etiological agents behind a number of pathological states
[43] including cardiovascular and neuro-degenerative dis-
eases [44], cancers, and aging in general [45]. Endocan-
nabinoids are specific immunological homeostatic
modulators when acting on "peripheral" CB2 receptors
[30]. Both endo- and exo-cannabinoids push the immune
system towards the relatively anti-inflammatory Th2
cytokine profile [46]. Thus, cannabinoids inhaled in can-
nabis smoke physiologically reduce the potential amplifi-
cation of carcinogens in smoke that results from
biologically produced free radicals. This response is not
induced by tobacco smoke.
In conclusion, while both tobacco and cannabis smoke
have similar properties chemically, their pharmacological
activities differ greatly. Components of cannabis smoke
minimize some carcinogenic pathways whereas tobacco
smoke enhances some. Both types of smoke contain car-
cinogens and particulate matter that promotes inflamma-
tory immune responses that may enhance the
carcinogenic effects of the smoke. However, cannabis typ-
ically down-regulates immunologically-generated free
radical production by promoting a Th2 immune cytokine
profile. Furthermore, THC inhibits the enzyme necessary
to activate some of the carcinogens found in smoke. In
contrast, tobacco smoke increases the likelihood of car-
cinogenesis by overcoming normal cellular checkpoint
protective mechanisms through the activity of respiratory
epithelial cell nicotine receptors. Cannabinoids receptors
have not been reported in respiratory epithelial cells (in
skin they prevent cancer), and hence the DNA damage
checkpoint mechanism should remain intact after pro-
longed cannabis exposure. Furthermore, nicotine pro-
motes tumor angiogenesis whereas cannabis inhibits it. It
is possible that as the cannabis-consuming population
ages, the long-term consequences of smoking cannabis
may become more similar to what is observed with
tobacco. However, current knowledge does not suggest
that cannabis smoke will have a carcinogenic potential
comparable to that resulting from exposure to tobacco
smoke.
It should be noted that with the development of vaporiz-
ers, that use the respiratory route for the delivery of carcin-
ogen-free cannabis vapors, the carcinogenic potential of
smoked cannabis has been largely eliminated [47,48].
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